Hereditary Angioedema - Market Insights, Epidemiology and Market Forecast – 2025

September 2017 | 99 pages | ID: H6921CBE432EN
DelveInsight

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight’s “Hereditary Angioedema - Market Insights, Epidemiology and Market Forecast – 2025” report provides an overview of the disease and in depth research related to Hereditary Angioedema for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Hereditary Angioedema . It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Hereditary Angioedema for 7 major markets.

The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, the Report highlights the frontrunners, the drivers and barriers for the Hereditary Angioedema market, as well as treatment algorithm, current treatments & advancements are included.The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Hereditary Angioedema , providing an in-depth analysis of emerging therapies which will create an impact through their launch.

According to DelveInsight, the forecasted patient population of Hereditary Angioedema for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Hereditary Angioedema 7MM market size is estimated to be USD XX by 2025.The DelveInsight Report will help in enhanced understanding of the Hereditary Angioedema market from inside out, with transparency into the calculated patient forecasting data and estimated market size.

Key Coverage

• Understanding historical and forecasted epidemiological data for Hereditary Angioedema covering 7MM from 2015-2025.
• Segment level epidemiology and market split for Hereditary Angioedema .
• The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for Hereditary Angioedema .
• The Report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and Japan) from 2015-2025 and detailed historical and forecasted Hereditary Angioedema market trends.
• Thorough market distribution based on market share for Hereditary Angioedema .

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Hereditary Angioedema market.
• To understand the future market competition in the Hereditary Angioedema market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Hereditary Angioedema in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
• Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.

Contents

1. REPORT INTRODUCTION

2. HEREDITARY ANGIOEDEMA MARKET OVERVIEW AT A GLANCE: GLOBAL (2015-2025)

2.1. Total Market Share Distribution of Hereditary Angioedema for 7 MM in 2016
2.2. Total Market Share Distribution of Hereditary Angioedema for 7 MM in 2025

3. HEREDITARY ANGIOEDEMA (HAE)

3.1. Overview
3.2. Types of Hereditary Angioedema (HAE)
3.3. Symptoms
3.4. Pathophysiology
3.5. Diagnosis
3.6. Diagnostic Algorithm
3.7. Treatment
3.8. Prophylaxis Algorithm

4. EPIDEMIOLOGY AND PATIENT POPULATION

4.1. Key Findings
4.2. Total number of Prevalent cases – 7MM Countries – (2016 & 2025)
4.3. Total number of Prevalent cases – Region wise – (2016 & 2025)
4.4. Distribution of Prevalent cases – 7MM Countries – (2016)

5. UNITED STATES

5.1. Prevalent Cases of Hereditary Angioedema in United States
5.2. Distribution of Hereditary Angioedema - By Types
5.3. Prevalent Cases of Hereditary Angioedema - By Type

6. GERMANY

6.1. Prevalent Cases of Hereditary Angioedema in Germany
6.2. Distribution of Hereditary Angioedema - By Types
6.3. Prevalent Cases of Hereditary Angioedema - By Type

7. FRANCE

7.1. Prevalent Cases of Hereditary Angioedema in France
7.2. Distribution of Hereditary Angioedema - By Types
7.3. Prevalent Cases of Hereditary Angioedema - By Type

8. UNITED KINGDOM

8.1. Prevalent Cases of Hereditary Angioedema in United Kingdom
8.2. Distribution of Hereditary Angioedema - By Types
8.3. Prevalent Cases of Hereditary Angioedema - By Type

9. SPAIN

9.1. Prevalent Cases of Hereditary Angioedema in Spain
9.2. Distribution of Hereditary Angioedema - By Types
9.3. Prevalent Cases of Hereditary Angioedema - By Type

10. ITALY

10.1. Prevalent Cases of Hereditary Angioedema in Italy
10.2. Distribution of Hereditary Angioedema by Types
10.3. Prevalent Cases of Hereditary Angioedema in by type - Italy

11. JAPAN

11.1. Prevalent Cases of Hereditary Angioedema in Japan
11.2. Distribution of Hereditary Angioedema by Types
11.3. Prevalent Cases of Hereditary Angioedema in by type - Japan

12. EMERGING THERAPIES

13. SHP643

13.1. Product Profile
13.2. Clinical Development
13.3. Clinical Pipeline Activity
13.4. Ongoing Trials Information
13.5. Clinical Trial by Phase

14. PHASE II

15. BCX7353

15.1. Product Profile
15.2. Clinical Development
15.3. Clinical Pipeline Activity
15.4. Ongoing Trials Information
15.5. Clinical Trial by Phase

16. RUCONEST

16.1. Product Profile
16.2. Clinical Development
16.3. Clinical Pipeline Activity
16.4. Ongoing Trials Information
16.5. Clinical Trial by Phase

17. KALBITOR

17.1. Product Profile
17.2. Clinical Pipeline Activity
17.3. Ongoing Trials Information
17.4. Clinical Trial by Phase

18. MARKETED DRUGS FOR HEREDITARY ANGIOEDEMA

19. BERINERT: CSL BEHRING GMBH

19.1. Drug Description
19.2. Regulatory Milestones
19.3. Advantages & Disadvantages
19.4. Safety and Efficacy of Berinert
19.5. Product Profile

20. CINRYZE: SHIRE

20.1. Drug Description
20.2. Regulatory Milestones
20.3. Advantages & Disadvantages
20.4. Safety and Efficacy of Cinryze
20.5. Product Profile

21. RUCONEST: PHARMING TECHNOLOGIES

21.1. Drug Description
21.2. Regulatory Milestones
21.3. Advantages & Disadvantages
21.4. Safety and Efficacy of Ruconest
21.5. Product Profile

22. KALBITOR: SHIRE

22.1. Drug Description
22.2. Regulatory Milestones
22.3. Advantages & Disadvantages
22.4. Safety and Efficacy of Kalbitor
22.5. Product Profile

23. FIRAZYR: SHIRE

23.1. Drug Description
23.2. Regulatory Milestones
23.3. Advantages & Disadvantages
23.4. Safety and Efficacy of Firazyr
23.5. Product Profile

24. HAEGARDA: CSL BEHRING

24.1. Drug Description
24.2. Regulatory Milestones
24.3. Advantages & Disadvantages
24.4. Safety and Efficacy of Firazyr
24.5. Product Profile

25. HEREDITARY ANGIOEDEMA MARKET OVERVIEW: 7MM

25.1. Overview on Total Hereditary Angioedema Market (2016 & 2025)
25.2. 7MM Hereditary Angioedema Market size (2016)
25.3. 7MM Hereditary Angioedema Market size (2025)
25.4. Global Hereditary Angioedema: Market Analysis

26. UNITED STATES MARKET SIZE

27. EUROPE MARKET SIZE

27.1. Germany Market Size
27.2. France Market Size
27.3. United Kingdom Market Size
27.4. Spain Market Size
27.5. Italy Market Size

28. JAPAN MARKET SIZE

29. MARKET DRIVERS

30. MARKET BARRIERS

31. REPORT METHODOLOGY

32. CONSULTING SERVICES

33. DISCLAIMER

34. ABOUT DELVEINSIGHT

List Of Tables

LIST OF TABLES

Table 1: Global Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Table 2: Total number of Hereditary Angioedema patient – 7MM (2016)
Table 3: Total number of Hereditary Angioedema patient – Region wise (2016 & 2025)
Table 4: Distribution of Prevalent cases – 7MM Countries – (2016)
Table 5: Prevalent Cases Hereditary Angioedema in United States (2015-2025)
Table 6: Percentage Distribution of Hereditary Angioedema by Types in United States (2016)
Table 7: Prevalent Cases of Hereditary Angioedema in United States by type (2015-2025)
Table 8: Prevalent Cases Hereditary Angioedema in Germany (2015-2025)
Table 9: Distribution of Hereditary Angioedema by Types in Germany (2016)
Table 10: Prevalent Cases of Hereditary Angioedema in Germany by type (2015-2025)
Table 11: Prevalent Cases Hereditary Angioedema in France (2015-2025)
Table 12: Distribution of Hereditary Angioedema by Types in France (2016)
Table 13: Prevalent Cases of Hereditary Angioedema in France by type (2015-2025)
Table 14: Prevalent Cases Hereditary Angioedema in United Kingdom (2015-2025)
Table 15: Distribution of Hereditary Angioedema by Types in United Kingdom (2016)
Table 16: Prevalent Cases of Hereditary Angioedema in United Kingdom by type (2015-2025)
Table 17: Prevalent Cases Hereditary Angioedema in Spain (2015-2025)
Table 18: Distribution of Hereditary Angioedema by Types in Spain (2016)
Table 19: Prevalent Cases of Hereditary Angioedema in Spain by type (2015-2025)
Table 20: Prevalent Cases Hereditary Angioedema in Italy (2015-2025)
Table 21: Distribution of Hereditary Angioedema by Types in Italy (2016)
Table 22: Prevalent Cases of Hereditary Angioedema in Italy by type (2015-2025)
Table 23: Prevalent Cases Hereditary Angioedema in Japan (2015-2025)
Table 24: Distribution of Hereditary Angioedema by Types in Japan (2016)
Table 25: Prevalent Cases of Hereditary Angioedema in Japan by type (2015-2025)
Table 26: SHP643, Clinical Trials by Zone, 2017
Table 27: Clinical Trials by Trial status, 2017
Table 28: BCX7353, Clinical Trials by Zone, 2017
Table 29: Clinical Trials by Trial status, 2017
Table 30: Ruconest, Clinical Trials by Zone, 2017
Table 31: Clinical Trials by Trial status, 2017
Table 32: Kalbitor, Clinical Trials by Zone, 2017
Table 33: Clinical Trials by Trial status, 2017
Table 34: 7 MM Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Table 35: 7 Major Market Size of Hereditary Angioedema in USD Million, (2016 & 2025)
Table 36: 7 Major Market Size of Hereditary Angioedema Market, USD Million (2016)
Table 37: 7 Major Market Size of Hereditary Angioedema Market, USD Million (2025)
Table 38: United States Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Table 39: Germany Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Table 40: France Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Table 41: United Kingdom Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Table 42: Spain Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Table 43: Italy Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Table 44: Japan Market Size of Hereditary Angioedema in USD Million, (2015-2025)

List Of Figures

LIST OF FIGURES

Figure 1: Types of Hereditary Angioedema (HAE)
Figure 2: Pathophysiology of Hereditary Angioedema
Figure 3: Prevalent Cases of Hereditary Angioedema in United States (2015-2025)
Figure 4: Percentage Distribution of Hereditary Angioedema by Types in United States (2016)
Figure 5: Prevalent Cases of Hereditary Angioedema in United States by type (2015-2025)
Figure 6: Prevalent Cases of Hereditary Angioedema in Germany (2015-2025)
Figure 7: Distribution of Hereditary Angioedema by Types in Germany (2016)
Figure 8: Prevalent Cases of Hereditary Angioedema in Germany by type (2015-2025)
Figure 9: Prevalent Cases of Hereditary Angioedema in France (2015-2025)
Figure 10: Distribution of Hereditary Angioedema by Types in France (2016)
Figure 11: Prevalent Cases of Hereditary Angioedema in France by type (2015-2025)
Figure 12: Prevalent Cases of Hereditary Angioedema in United Kingdom (2015-2025)
Figure 13: Distribution of Hereditary Angioedema by Types in United Kingdom (2016)
Figure 14: Prevalent Cases of Hereditary Angioedema in United Kingdom by type (2015-2025)
Figure 15: Prevalent Cases of Hereditary Angioedema in Spain (2015-2025)
Figure 16: Distribution of Hereditary Angioedema by Types in Spain (2016)
Figure 17: Prevalent Cases of Hereditary Angioedema in Spain by type (2015-2025)
Figure 18: Prevalent Cases of Hereditary Angioedema in Italy (2015-2025)
Figure 19: Distribution of Hereditary Angioedema by Types in Italy (2016)
Figure 20: Prevalent Cases of Hereditary Angioedema in Italy by type (2015-2025)
Figure 21: Prevalent Cases of Hereditary Angioedema in Japan (2015-2025)
Figure 22: Distribution of Hereditary Angioedema by Types in Japan (2016)
Figure 23: Prevalent Cases of Hereditary Angioedema in Japan by type (2015-2025)
Figure 24: SHP643, Clinical Trials by Zone (%), 2017
Figure 25: SHP643, Clinical Trials by Trial status (%), 2017
Figure 26: BCX7353, Clinical Trials by Zone (%), 2017
Figure 27: BCX7353, Clinical Trials by Trial status (%), 2017
Figure 28: Ruconest, Clinical Trials by Zone (%), 2017
Figure 29: Ruconest, Clinical Trials by Trial status (%), 2017
Figure 30: Kalbitor, Clinical Trials by Zone (%), 2017
Figure 31: Kalbitor, Clinical Trials by Trial status (%), 2017
Figure 32: 7 Major Market Size of Hereditary Angioedema in USD Million, (2016 & 2025)
Figure 33: 7 Major Market Size of Hereditary Angioedema Market, USD Million (2016)
Figure 34: 7 Major Market Size of Hereditary Angioedema Market, USD Million (2025)
Figure 35: United States Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Figure 36: Germany Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Figure 37: France Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Figure 38: United Kingdom Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Figure 39: Spain Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Figure 40: Italy Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Figure 41: Japan Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Figure 42: Market Drivers for Hereditary Angioedema
Figure 43: Market Barriers for Hereditary Angioedema